ARTICLE | Cover Story
LIGHTs out for asthma
May 5, 2011 7:00 AM UTC
Two years after Kyowa Hakko Kirin Co. Ltd.granted sanofi-aventis Groupan exclusive license to an antibody against the tumor necrosis factor ligand LIGHT to treat irritable bowel disease, researchers at the La Jolla Institute for Allergy & Immunology have now uncovered an even larger indication for the target-asthma.
The new findings suggest that inhibiting tumor necrosis factor ligand superfamily member 14 (TNFSF14; LIGHT; CD258) could prevent airway remodeling in asthma.1...